Medexus Pharmaceuticals Inc is seeing a significant rise in its stock price, reflecting positive investor sentiment.
Medexus Pharmaceuticals Inc (MDP.TO) is up today, gaining 6.85% to close at CA$5.30. This increase highlights the company's potential as it continues to progress in the pharmaceutical sector.
Advertisement
Medexus Pharmaceuticals Inc
MDP.TO
MDP.TO
Medexus Pharmaceuticals Inc
WealthAwesomeAdvertisement
Market cap
$157.04M
52W high
$5.38
52W low
$2.47
1W change
+6.21%
Beta
1.84
Analyst Price Targets
Based on analyst covering MDP
Wall Street analysts forecast MDP stock price to rise 28.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.81
+28.5% Upside
Current Price
C$5.30
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDP's historical volatility
30-Day Vol
51.2%
Annualized
90-Day Vol
41.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$6.34
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$5.63 | C$4.71 – C$6.71 |
| 60 trading days | C$5.97 | C$4.65 – C$7.66 |
| 90 trading days | C$6.34 | C$4.67 – C$8.60 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Keep an eye on Medexus as it shows strong performance, especially with its GRAFAPEX product, which has been well-received in the market.
6.85% Gain
Medexus Pharmaceuticals Inc's stock has surged by 6.85% today, showing strong market interest.
Bull case
The company's recent fiscal year results reveal solid performance, particularly for GRAFAPEX (treosulfan) for Injection. This could attract more investor interest and lead to further stock price growth.
Bear case
Despite today's positive movement, Medexus faces challenges, including a negative profit margin that could affect long-term profitability and investor confidence.
Strong Performance Metrics
Advertisement
Medexus Pharmaceuticals has reported strong fiscal results, especially for its GRAFAPEX product. Investors are responding positively to these metrics, indicating confidence in the company's growth trajectory. For more details, check out the Medexus stock page.
Market Sentiment and Future Prospects
The rise in Medexus's stock price today reflects favorable market sentiment. As the company continues to innovate and expand its product offerings, investors are optimistic about future growth. Dive deeper into the latest updates on Medexus to stay informed.
Understanding the Risks
While the stock is performing well today, potential investors should be aware of the risks involved, including the company's current negative profit margin. It's essential to consider these factors before making investment decisions. For more insights, visit the Medexus stock page.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
